Impact of age, sex and route of administration on adverse events after opioid treatment in the emergency department: A retrospective study

Raoul Daoust MD MSc1,2, Jean Paquet PhD1,3, Gilles Lavigne DMD PhD3,4, Éric Piette MD MSc1,2, Jean-Marc Chauny MD MSc1,2

OBJECTIVE: To assess the impact of age, sex and route of administration on the incidence of adverse events due to opioid administration in the ED.

METHODS: Real-time archived data were analyzed retrospectively in a tertiary care urban hospital. All consecutive patients (216 years of age) who were assigned to an ED bed and received an opioid between March 2008 and December 2012 were included. Adverse events were defined as nausea/vomiting (minor); systolic blood pressure (SBP) <90 mmHg, oxygen saturation (SaO2) <92% and respiration rate <10 breaths/min (major) within 2 h of the first opioid doses.

RESULTS: In the study period, 31,742 patients were treated with opioids. The mean (± SD) age was 55.8±20.5 years, and 53% were female. The overall incidence of adverse events was 12.0% (95% CI 11.6% to 12.4%): 5.9% (95% CI 5.6% to 6.2%) experienced nausea/vomiting, 2.4% (95% CI 2.2% to 2.6%) SBP <90 mmHg, 4.7% (95% CI 4.5% to 4.9%) SaO2 that dropped to <92% and 0.09% respiration rate <10 breaths/min. After controlling for confounding factors, these adverse events were associated with: female sex (more nausea/vomiting, more SBP <90 mmHg, less SaO2 <92%); age 65 years (less nausea/vomiting, more SBP <90 mmHg, more SaO2 <92%); and route of administration (intravenous > subcutaneous > oral).

CONCLUSIONS: The incidence of adverse events associated with opioid administration in the ED is generally low and is associated with age, sex and route of administration.

Key Words: Adverse events; Age effect; Emergency department; Sex; Opioid administration

OPEN ACCESS This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact support@pulsus.com

Pain Res Manag Vol 20 No 1 January/February 2015 23
Methods

Study design and setting

Real-time, archived data from a computerized system used in the ED of a tertiary, academic, urban hospital with an annual census of approximately 60,000 ED visits were retrospectively analyzed. This computerized system includes demographic data, triage information as well as pertinent data collected by nurses during ED visits, such as medication prescribed (type, route of administration and time of treatment), observations relative to side effects or adverse events from medication administration and subsequent evaluations of vital signs. All data were collected in real time and were time-stamped. The study was approved by the institutional ethics review board.

Selection of participants

All consecutive patients ≥16 years of age assigned to an ED bed and who received an opioid treatment between March 2008 and December 2012 were selected. To ensure sufficient data for statistical comparisons, the search was restricted to the most common opioid/route of administration combinations, which represented at least 90% of all opioid treatments given in the ED. To eliminate possible medication or route of administration interaction effects, patients who received more than one type of opioid or route of administration during the study period were excluded from the final analysis. For example, patients who received two types of opioids PO or the same opioid PO and IV were excluded. Patients who received opioids for palliative care, pregnant women (due to physiological differences) and patients transferred from or to another hospital (who may have received an opioid treatment before the initial recorded opioid dose) were also excluded.

Data collection and outcome

Sex, age, triage level (high = 1 or 2 versus low = 3, 4 or 5), means of arrival (walk-in or ambulance), time of arrival at and release from the ED, disposition (admitted or discharged), comorbidities, history of asthma or chronic obstructive pulmonary disease (COPD), coanalgiesia (nonopioids) before opioid administration, benzodiazepine use before opioid administration, tachycardia (heart rate >100 beats/min) and fever (oral temperature >37.8°C) before opioid administration, and vital signs before and 2 h after opioid administration were extracted from the database.

For equivalent comparisons between opioid/route combinations, the initial cumulative doses that patients received was computed as a morphine equipotent parenteral (MEP) dose of 1 mg: 1 MEP equals 1 mg of parenteral morphine, 3 mg of oral morphine, 2 mg of oral oxycodone, 0.01 mg of parenteral fentanyl, 0.15 mg of parenteral hydromorphone and 0.75 mg of oral hydromorphone (17).

The primary outcome was the presence of one or more adverse events within 2 h of the first opioid dose; these events are defined in the present study as adverse events. As in previous studies, nausea/vomiting was considered a minor adverse event, and systolic blood pressure (SBP) <90 mmHg, Sat <92% and respiration rate (RR) <10 breaths/min were considered to be major adverse events. Global adverse events refers to minor and major adverse events combined. These adverse events were retained because they are the most clinically significant. Information regarding delirium or level of sedation in the database used in the present study was not sufficiently reliable to be reported, and desaturation was used as a surrogate for sedation. To be identified, these adverse events had to be absent before the opioid administration and occur within 2 h after initial opioid doses. Whether patients with adverse events differed with regard to ED length of stay or rate of hospital admission compared with patients without adverse events was also evaluated.

Statistical analysis

One-way ANOVAs were used to compare the effects of eight opioid/route combinations on vital signs. Univariate associations between adverse events and patient/treatment characteristics were assessed using χ² tests and t tests for independent groups. Because of the large sample size, Cohen's effect sizes (ESs) are reported instead of significance level. To interpret the importance of different ESs, Cohen designated 0.1 as small, 0.3 as medium, and 0.5 as large from one-way ANOVAs. Multivariate logistic regression analyses examined the unique contribution of sex, age, route of administration and type of opioid to each adverse event, controlling for confounding factors: MEP, coanalgiesia, benzodiazepine use, number of comorbidities, history of asthma or COPD, tachycardia or fever. The logistic regression results are reported with ORs (higher risk if >1 and lower risk if <1) and associated 95% CIs. The alpha level was set at 0.05 for ORs. All data were analyzed using SPSS version 20 (IBM Corporation, USA).

Results

The eight most common opioid/route combinations, which included 98% of all opioid treatments given in our ED, were: morphine/IV (30.1%), oxycodone/PO (27.2%), fentanyl/IV (20.7%), hydromorphone/PO (6.4%), morphine/SC (5.6%), morphine/PO (3.7%), hydromorphone/SC (3.2%) and hydromorphone/IV (1.1%). During the targeted study period, 32,623 patients received one of the eight combinations. Some patients (2.7%) were excluded because they received multiple types of opioid treatment during the study period or met other exclusion criteria, leaving a total of 31,742 patients eligible for final analysis. Patient characteristics are summarized in Table 1. The mean patient age was 55.8±20.5 years, and 53% were female. More than one-half of patients received IV treatments (mainly morphine and fentanyl). Oxycodone was the medication used most often, through the PO route of administration. Table 2 displays the vital signs before (ie, the measurement closest to) opioid administration as a function of the eight opioid/route combinations. Before opioid administration, vital signs were clinically similar for all opioid/route combinations (with small ESs ranging from 0.10 to 0.14). The incidence of RR

**Table 1. Hospital and patient characteristics for the entire sample (n=31,742)**

| Characteristic |    |
|---------------|----|
| Emergency department bed patients per year, n | 25,107 |
| Age, years  |    |
| <65         | 64.3 |
| ≥65         | 35.7 |
| Sex         |    |
| Male        | 47.5 |
| Female      | 52.5 |
| Triage priority |    |
| High (1 or 2) | 44.9 |
| Low (3, 4 or 5) | 55.1 |
| Type of arrival |    |
| Walk-in     | 47.3 |
| Ambulance   | 52.7 |
| Route of administration |    |
| Intravenous | 52.8 |
| Subcutaneous| 9.1 |
| Oral        | 38.1 |
| Coanalgesia | 41.0 |
| Disposition after emergency department |    |
| Discharged  | 47.0 |
| Admitted    | 53.0 |
| Visit duration, h, median (Q25–Q75) | 15.8 (8.4–26.2) |

Data presented as % unless otherwise indicated. Q Quartile

65 years of age would experience greater oxygen saturation (Sat) declines compared with younger subjects.
adverse events after opioid administration in the ED

The overall incidence of adverse events was generally low: 5.9% (95% CI 5.6% to 6.2%) of patients experienced nausea/vomiting, 2.4% (95% CI 2.2% to 2.6%) SBP <90 mmHg, 4.7% (95% CI 4.5% to 4.9%) Sat <92% and 12.0% (95% CI 11.6% to 12.4%) reported at least one of these three adverse events. Table 3 reports associations between each adverse event and sex, age, administration route, opioid
dose, co-morbidity, history of asthma or COPD, history of tachycardia, history of fever, co-analgesia, and opioid type.

**Table 2**

| Opioid/route combination | Heart rate, beats/min | Systolic blood pressure, mmHg | Oxygen saturation, % | Respiratory rate, breaths/min |
|--------------------------|-----------------------|-------------------------------|----------------------|------------------------------|
| Morphine/intravenous     | 81.3±16.6             | 135.2±21.8                    | 97.5±1.9             | 17.8±3.3                     |
| Oxycodone/oral           | 80.0±15.3             | 133.3±21.7                    | 97.2±2.0             | 17.2±2.6                     |
| Fentanyl/intravenous     | 84.9±20.0             | 129.3±24.5                    | 97.1±2.3             | 15.1±3.9                     |
| Hydromorphone/oral       | 82.1±16.1             | 132.1±21.6                    | 96.8±2.1             | 17.4±2.7                     |
| Morphine/subcutaneous    | 63.9±17.7             | 131.1±22.6                    | 96.8±2.5             | 18.2±3.7                     |
| Morphine/oral            | 80.6±15.3             | 132.7±20.9                    | 96.9±2.1             | 17.3±2.6                     |
| Hydromorphone/subcutaneous | 84.8±17.8           | 130.8±21.0                    | 97.1±2.2             | 17.7±2.9                     |
| Hydromorphone/intravenous | 83.5±17.1            | 133.0±21.5                    | 97.5±1.9             | 17.9±3.3                     |

Effect size 0.11 0.10 0.12 0.14

Data presented as mean ± SD unless otherwise indicated. Effect size was calculated by one-way ANOVAs.

**Table 3**

| Variable | Nausea/vomiting | SBP <90 mmHg | Saturation <92% | Major adverse events | Global adverse events |
|----------|-----------------|--------------|-----------------|----------------------|-----------------------|
| Overall (n=31,742) | 5.9 | 4.7 | 6.7 | 12.0 |

| Sex | % | ES | % | ES | % | ES | % | ES |
|-----|---|---|---|---|---|---|---|---|
| Male | 5.0 | 0.04 | 2.3 | <0.001 | 5.3 | 0.03 | 7.3 | 0.02 | 11.6 | 0.01 |
| Female | 6.6 | 2.4 | 4.1 | 6.2 | 12.3 |

| Age, years | % | ES | % | ES | % | ES | % | ES |
|------------|---|---|---|---|---|---|---|---|
| <65 | 6.7 | 0.05 | 2.2 | 0.01 | 4.0 | 0.04 | 6.0 | 0.04 | 12.0 | 0.002 |
| ≥65 | 4.5 | 2.6 | 5.8 | 8.0 | 11.9 |

| Opioid dose, MEP, mean ± SD | % | ES | % | ES | % | ES | % | ES |
|-----------------------------|---|---|---|---|---|---|---|---|
| With adverse event | 7.1±4.5 | 0.44* | 7.7±6.3 | 0.46* | 7.6±4.9 | 0.53* | 7.6±5.3 | 0.53* | 7.4±5.0 | 0.51* |
| Without adverse events | 5.2±4.1 | 5.3±4.1 | 5.2±4.1 | 5.2±4.0 | 5.1±4.0 |

| Comorbidity | % | ES | % | ES | % | ES | % | ES |
|-------------|---|---|---|---|---|---|---|---|
| 0 | 6.5 | 0.03 | 3.3 | 0.04 | 4.1 | 0.03 | 7.0 | 0.02 | 12.7 | 0.01 |
| 1 | 6.7 | 1.9 | 4.3 | 5.9 | 12.0 |
| >1 | 5.2 | 2.0 | 5.2 | 7.0 | 11.5 |

| History of asthma or COPD | % | ES | % | ES | % | ES | % | ES |
|---------------------------|---|---|---|---|---|---|---|---|
| Yes | 4.6 | 0.02 | 2.6 | 0.005 | 5.1 | 0.007 | 7.4 | 0.009 | 11.6 | 0.004 |
| No | 6.1 | 2.3 | 4.6 | 6.6 | 12.0 |

| Coanalgesia | % | ES | % | ES | % | ES | % | ES |
|-------------|---|---|---|---|---|---|---|---|
| Yes | 4.8 | 0.04 | 1.5 | 0.05 | 3.4 | 0.05 | 4.8 | 0.06 | 9.2 | 0.07 |
| No | 6.6 | 3.0 | 5.5 | 8.1 | 13.9 |

| With benzodiazepine | % | ES | % | ES | % | ES | % | ES |
|---------------------|---|---|---|---|---|---|---|---|
| Yes | 11.3 | 0.09 | 3.1 | 0.02 | 5.6 | 0.02 | 8.3 | 0.02 | 18.5 | 0.08 |
| No | 5.1 | 2.2 | 4.5 | 6.5 | 11.0 |

| With tachycardia | % | ES | % | ES | % | ES | % | ES |
|------------------|---|---|---|---|---|---|---|---|
| Yes | 6.4 | 0.008 | 4.5 | 0.06 | 5.3 | 0.01 | 9.3 | 0.04 | 14.8 | 0.04 |
| No | 5.8 | 2.0 | 4.5 | 6.3 | 11.5 |

| With fever | % | ES | % | ES | % | ES | % | ES |
|------------|---|---|---|---|---|---|---|---|
| Yes | 4.3 | 0.02 | 2.8 | 0.008 | 5.0 | 0.004 | 7.4 | 0.008 | 11.2 | 0.007 |
| No | 6.0 | 2.3 | 4.6 | 6.7 | 12.0 |

| Administration route | % | ES | % | ES | % | ES | % | ES |
|---------------------|---|---|---|---|---|---|---|---|
| Oral | 2.4 | 0.12 | 0.6 | 0.10 | 1.2 | 0.14 | 1.8 | 0.17 | 4.0 | 0.21 |
| Subcutaneous | 5.7 | 1.7 | 2.6 | 4.1 | 9.3 |
| Intravenous | 8.5 | 3.7 | 7.5 | 10.7 | 18.2 |

| Opioid type | % | ES | % | ES | % | ES | % | ES |
|-------------|---|---|---|---|---|---|---|---|
| Oxycodone | 2.5 | 0.10 | 0.7 | 0.13 | 1.2 | 0.12 | 1.8 | 0.15 | 4.1 | 0.17 |
| Fentanyl | 7.2 | 6.1 | 6.5 | 11.7 | 18.0 |
| Morphine | 7.9 | 1.9 | 6.6 | 8.3 | 15.4 |
| Hydromorphone | 4.5 | 1.0 | 2.8 | 3.7 | 7.9 |

<10 breaths/min was negligible (0.09%) and, therefore, was not reported in subsequent analyses.

The overall incidence of adverse events was generally low: 5.9% (95% CI 5.6% to 6.2%) of patients experienced nausea/vomiting, 2.4% (95% CI 2.2% to 2.6%) SBP <90 mmHg, 4.7% (95% CI 4.5% to 4.9%) Sat <92% and 12.0% (95% CI 11.6% to 12.4%) reported at least one of these three adverse events.
type and confounding factors. The effect of dose was significant for all adverse events; patients with adverse events received a mean MEP dose that was 1.5 times higher than that of patients without adverse events. Administration route and opioid type were associated with adverse events; ESs ranged from 0.10 to 0.21. However, significant ESs with opioid type were expected; this is likely attributable to the unique administration route for certain opioids (ie, oxycodone is only available PO).

After controlling for confounding factors, adverse events were associated with female sex (more nausea/vomiting, more SBP <90 mmHg, fewer Sat <92% events) and age ≥65 years (more SBP <90 mmHg, more Sat <92%, fewer nausea/vomiting events). The IV route was linked with higher rates of all adverse events, the SC route with moderate rates, and the PO route with fewer overall rates (Table 4). Higher opioid doses were generally associated with more adverse events, a history of asthma or COPD ≥65 years (more oxygen desaturation events) and age ≥65 years of age have more oxygen desaturation events ≥65 years (more oxygen desaturation events). The incidence of nausea/vomiting, SBP <90 mmHg or Sat <92% events after opioid administration in the ED was generally low (12%), but it did not appear to differ in patients with or without adverse events. A higher hospital admission rate was observed for patients with SBP <90 mmHg; however, the effect size was small.

**DISCUSSION**

The incidence of nausea/vomiting, SBP <90 mmHg or Sat <92% events after opioid administration in the ED was generally low (12%), but it was clearly associated with age, sex, dose and administration route. Our hypothesis – that the IV administration route produces more adverse events than the SC/PO routes – was confirmed, as observed by others (8). Moreover, the administration route is the most prominent factor influencing adverse events, with the IV route presenting a fourfold increase in the odds of producing nausea/vomiting or a SBP decline and a sevenfold increase in desaturation induction compared with the PO route. Our results show that the SC route has higher ORs (ranging from 1.5 to 2.6) for eliciting adverse events than the PO route.

We have also confirmed findings from previous studies with much smaller sample sizes: women have more nausea/vomiting events than men, patients ≥65 years of age have more oxygen desaturation events.
than younger subjects (5-8), and higher opioid doses are associated with more adverse events, but this appears to be less significant than the effect of administration route (9-11). Women appear to report more intense, numerous and frequent physical symptoms compared with men. This could be explained by an innate difference in somatic and visceral perception (18). The findings that patients ≥65 years of age have more oxygen desaturation events could be explained by pharmacokinetic and pharmacodynamic changes associated with age (8). Also interesting is the fact that older patients appear to be less affected by nausea/vomiting than younger patients and that women appear to be less prone to desaturation than men.

The very low incidence of RR <10 breaths/min events was surprising because RR is believed to decrease before a drop in oxygen saturation. This could be explained by the fact that nurses were more aware of oxygen desaturation compared with RR and, while they provide oxygen to patients, they may have neglected to document their RR.

Contrary to our expectations, nonopioid coanalgesia with opioid administration did not significantly reduce the risk of adverse events. A potential explanation could be the low concomitant use of nonopioid coanalgesia in our study population. However, benzodiazepine use before opioid administration appears to slightly increase the risk of adverse events. Finally, a history of asthma or COPD and tachycardia before opioid administration tends to augment the odds of SBP <90 mmHg events.

Fentanyl is usually believed to produce fewer SBP decreases (19,20). The present findings could be explained by the retrospective design of our study; patients were not randomly assigned to receive a specific opioid and, thus, fentanyl (being recognized as having less impact on blood pressure) could have been used for patients at risk for significantly decreased SBP and morphine could have been administered to more hemodynamically stable patients. Although we excluded all patients with SBP <90 mmHg events before administration of opioids in our definition of adverse events, the mean level of SBP immediately preceding opioid administration was slightly lower in patients receiving fentanyl IV than in patients receiving morphine (129.3 mmHg versus 134.3 mmHg; difference = 5.0 [95% CI 4.3 to 5.7]).

Contrary to the results of other studies (21), adverse events observed in our patients did not appear to impact ED length of stay, but they were associated with a higher percentage of hospital admissions, especially for patients with SBP <90 mmHg events after opioid treatment. However, the ESs were small and we are unable to determine whether all hospital admissions were directly related to adverse events. To our knowledge, this is the first time that adverse events associated with opioids have been associated with higher rate of hospital admissions. In a meta-analysis of prospective studies, Lazarou et al (21) demonstrated that adverse events (not specifically related to opioid treatment) were a significant cause of hospital admissions, and Davies et al (22) showed that opioids were frequently associated with adverse events in hospitalized patients. Kongkaew et al (23), however, could not implicate opioids as a significant source of adverse events and hospital admission.

**REFERENCES**

1. Innes G, Murphy M, Nijssen-Jordan C, Ducharme J, Drummond A. Procedural sedation and analgesia in the emergency department. Canadian Consensus Guidelines. J Emerg Med 1999;17:145-56.
2. Smith MD, Wang Y, Cudnik M, Smith DA, Pakiela J, Emerman CL. The effectiveness and adverse events of morphine versus fentanyl on a physician-staffed helicopter. J Emerg Med 2012;43:69-75.
3. McPherson ML. Strategies for the management of opioid-induced adverse events. Adv Surg Pharmac 2008;5:552-7.
4. Niemi-Murola L, Unkuri J, Hamunen K. Parenteral opioids in emergency medicine – A systematic review of efficacy and safety. Scand J Pain 2011;2:187-94.
5. Bijur PE, Esses D, Birmbaum A, Chang AK, Schechter C, Gallagher EJ. Response to morphine in male and female patients: Analgesia and adverse events. Clin J Pain 2008;24:192-8.
6. Zun LS, Downey LV, Gossman W, Rosenbaum J, Sussman G. Gender differences in narcotic-induced emesis in the ED. Ann Emerg Med 2002;40:151-4.
7. Fillingim RB, Ness TJ, Glover TL, et al. Morphine responses and experimental pain: Sex differences in side effects and cardiovascular responses but not analgesia. J Pain 2005;6:116-24.
8. Cepeda MS, Farrar JT, Baumgarten M, Bostom A, Carr DB, Strom BL. Side effects of opioids during short-term administration: Effect of age, gender, and race. Clin Pharmacol Ther 2003;74:102-12.
9. O’Connor AB, Zwemer FL, Hays DP, Feng C. Intravenous opioid dosing and outcomes in emergency patients: A prospective cohort analysis. Am J Emerg Med 2010;28:1041-50, e6.
10. Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: A systematic review. J Pain 2002;3:159-80.
11. Wermeling DP, Clinch T, Rudy AG, Dreitlein D, Suner S, Lacouture FG. A multicenter, open-label, exploratory dose-ranging trial of intranasal hydromorphone for managing acute pain from traumatic injury. J Pain 2010;11:24-31.

**TABLE 5**

| Impact of adverse events on length of stay and hospital admission |
|---------------------------------------------------------------|
| Adverse events | Presence | Absence | Effect sizes |
|----------------|----------|---------|--------------|
| Median length of stay, h (25th–75th quartile) |
| Nausea/vomiting | 15.3 (8.6–24.2) | 15.8 (8.4–26.3) | 0.008* |
| SBP <90 mmHg | 12.8 (5.7–24.7) | 15.8 (8.4–26.2) | 0.03* |
| Oxygen saturation <92% | 16.3 (9.2–27.0) | 15.7 (8.3–26.2) | 0.01* |
| Major adverse events | 15.6 (8.1–26.2) | 15.8 (8.4–26.2) | 0.008* |
| Global adverse events | 15.5 (8.4–25.3) | 15.8 (8.4–26.3) | 0.009* |

*Effect sizes were calculated by the Mann-Whitney U-test. SBP Systolic blood pressure

Our study had potential limitations. Nausea/vomiting events were documented from a text search of nurses’ notes in the database. Though extensive text inclusion and exclusion criteria were used, some nausea/vomiting adverse events could have been missed. Additionally, it is possible that nurses omitted or forgot to report these adverse events because of their intense workload. However, database accuracy depends on personnel who enter data, and nurses as well as physicians are well aware of the importance of accurate and detailed charts. A formal survey in our hospital revealed that nurses always reported major adverse events (data not included). Furthermore, our retrospective study may have underestimated the rate of adverse events compared with a prospective study in which a research assistant would systematically ask a list of questions pertaining to adverse events. Finally, data on sleep apnea and obesity, which are factors that could impact the prevalence of oxygen desaturation, were not available in our database.

**CONCLUSION**

The present large retrospective study showed that the incidence of adverse events related to ED opioid treatment is generally low and is associated with age, sex and route of administration. This is in accordance with previous literature; however, large prospective studies on adverse events associated with opioid use and their impact are needed to confirm these results.

**DISCLOSURES:** The authors have no conflict of interest to declare.
12. Wenderoth BR, Kaneda ET, Amini A, Amiri R, Patanwala AE. Morphine versus fentanyl for pain due to traumatic injury in the emergency department. J Trauma Nurs 2013;20:10-5.
13. Serinken M, Eken C, Turkcuer I, Elicabuk H, Uyanik E, Schultz CH. Intravenous paracetamol versus morphine for renal colic in the emergency department: A randomised double-blind controlled trial. Emerg Med J 2012;29:902-5.
14. Jalili M, Fathi M, Moradi-Lakeh M, Zehtabchi S. Sublingual buprenorphine in acute pain management: A double-blind randomized clinical trial. Ann Emerg Med 2012;59:276-80.
15. Chang AK, Bijur PE, Gallagher EJ. Randomized clinical trial comparing the safety and efficacy of a hydromorphone titration protocol to usual care in the management of adult emergency department patients with acute severe pain. Ann Emerg Med 2011;58:356-9.
16. Bektas F, Eken C, Karadeniz O, Goksu E, Cubuk M, Cete Y. Intravenous paracetamol or morphine for the treatment of renal colic: A randomized, placebo-controlled trial. Ann Emerg Med 2009;54:568-74.
17. Berdine HJ, Nesbit SA. Equianalgesic dosing of opioids. J Pain Palliat Care Pharmacother 2006;20:79-84.
18. Barsky AJ, Peekna HM, Bonus JE. Somatic symptom reporting in women and men. J Gen Intern Med 2001;16:266-75.
19. Kanowitz A, Dunn TM, Kanowitz EM, Dunn WW, Vanbuskirk K. Safety and effectiveness of fentanyl administration for prehospital pain management. Prehosp Emerg Care 2006;10:1-7.
20. Soriya GC, McVaney KE, Liao MM, et al. Safety of prehospital intravenous fentanyl for adult trauma patients. J Trauma Acute Care Surg 2012;72:755-9.
21. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
22. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS One 2009;4:e4439.
23. Kongkaew C, Hann M, Mandal J, et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy 2013;33:827-37.